TY - JOUR
T1 - Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia
T2 - A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
AU - Ruggeri, Annalisa
AU - Galimard, Jacques Emmanuel
AU - Labopin, Myriam
AU - Rafii, Hanadi
AU - Blaise, Didier
AU - Ciceri, Fabio
AU - Diez-Martin, Jose Luiz
AU - Cornelissen, Jan
AU - Chevallier, Patrice
AU - Sanchez-Guijo, Fermin
AU - Nicholson, Emma
AU - Castagna, Luca
AU - Forcade, Edouard
AU - Kuball, Jürgen
AU - Rovira, Montserrat
AU - Koc, Yener
AU - Pavlu, Jiri
AU - Gulbas, Zafar
AU - Vydra, Jan
AU - Baron, Frederic
AU - Sanz, Jaime
AU - Spyridonidis, Alexandros
AU - Savani, Bipin
AU - Gluckman, Eliane
AU - Nagler, Arnon
AU - Mohty, Mohamad
N1 - Publisher Copyright:
© 2022 The American Society for Transplantation and Cellular Therapy
PY - 2022/10
Y1 - 2022/10
N2 - Unmanipulated haploidentical hematopoietic stem cell transplantation (HCT) with post-transplantation cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis (haplo-PTCY) and unrelated double-unit umbilical cord blood transplantation (dUCBT) are feasible options for treating patients with high-risk acute myelogenous leukemia (AML). This study compared outcomes after dUCBT and haplo-HCT using peripheral blood stem cells (PBSCs) in adult patients with AML in complete remission (CR) who underwent transplantation in European Society for Blood and Marrow Transplantation (EBMT)-affiliated centers. In a population of adults with de novo AML in first or second CR, we compared outcomes after dUCBT (n = 165) and after haplo-PTCY PBSC (n = 544) performed between January 2013 and December 2018. Patients receiving in vivo antithymocyte globulin, Campath, or ex vivo T cell depletion were excluded. The median follow-up was 33 months for the haplo-PTCY arm and 52 months for the dUCBT arm. No statistically significant differences were observed between the 2 arms in the rates of grade II-IV acute graft-versus-host disease (GVHD) (hazard ratio [HR], 1.31; P =. 18), grade III-IV acute GVHD (HR, 1.17; P =. 56), chronic GVHD (HR,. 86; P =. 48), relapse (HR, 1.07; P =. 77), nonrelapse mortality (NRM) (HR,. 94; P =. 77), leukemia-free survival (LFS) (HR,. 99; P =. 95), or overall survival (OS) (HR,. 99; P =. 97). Favorable cytogenetic risk was the sole factor predictive of lower relapse incidence (RI). Younger age at transplantation was associated with lower NRM and higher LFS and OS. Both dUCBT and haplo-PTCY with PBSCs can be considered valid approaches for adult AML patients in CR. New strategies should be investigated in both settings to define the most appropriate conditioning regimen and potentially decrease RI and NRM through better immune reconstitution and optimal supportive care.
AB - Unmanipulated haploidentical hematopoietic stem cell transplantation (HCT) with post-transplantation cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis (haplo-PTCY) and unrelated double-unit umbilical cord blood transplantation (dUCBT) are feasible options for treating patients with high-risk acute myelogenous leukemia (AML). This study compared outcomes after dUCBT and haplo-HCT using peripheral blood stem cells (PBSCs) in adult patients with AML in complete remission (CR) who underwent transplantation in European Society for Blood and Marrow Transplantation (EBMT)-affiliated centers. In a population of adults with de novo AML in first or second CR, we compared outcomes after dUCBT (n = 165) and after haplo-PTCY PBSC (n = 544) performed between January 2013 and December 2018. Patients receiving in vivo antithymocyte globulin, Campath, or ex vivo T cell depletion were excluded. The median follow-up was 33 months for the haplo-PTCY arm and 52 months for the dUCBT arm. No statistically significant differences were observed between the 2 arms in the rates of grade II-IV acute graft-versus-host disease (GVHD) (hazard ratio [HR], 1.31; P =. 18), grade III-IV acute GVHD (HR, 1.17; P =. 56), chronic GVHD (HR,. 86; P =. 48), relapse (HR, 1.07; P =. 77), nonrelapse mortality (NRM) (HR,. 94; P =. 77), leukemia-free survival (LFS) (HR,. 99; P =. 95), or overall survival (OS) (HR,. 99; P =. 97). Favorable cytogenetic risk was the sole factor predictive of lower relapse incidence (RI). Younger age at transplantation was associated with lower NRM and higher LFS and OS. Both dUCBT and haplo-PTCY with PBSCs can be considered valid approaches for adult AML patients in CR. New strategies should be investigated in both settings to define the most appropriate conditioning regimen and potentially decrease RI and NRM through better immune reconstitution and optimal supportive care.
KW - Acute myelogenous leukemia
KW - Double cord blood transplantation
KW - Haploidentical transplant
KW - Post-transplantation cyclophosphamide
UR - http://www.scopus.com/inward/record.url?scp=85139250811&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2022.07.006
DO - 10.1016/j.jtct.2022.07.006
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35830930
AN - SCOPUS:85139250811
SN - 2666-6367
VL - 28
SP - 710.e1-710.e10
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
IS - 10
ER -
